SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (4042)6/6/2001 4:27:49 PM
From: Biomaven  Read Replies (3) | Respond to of 52153
 
I've often talked on this thread about how much biotech stocks are sometimes driven in the short term by the "Old Economy/New Economy" dichotomy as measured by the ratio of the NASD to the DOW on the one hand and the biotechs (BTK) to the pharmas (DRG) on the other.

I finally got around to prevailing on one of my kids (thanks Ted!) to work some web/photoshop magic and put up some charts on the web so others can see this for themselves. Here are the comparative charts (10-minute intervals) for the last week or so:

24.147.1.28

We included an overlay to show just how close this match can be on a minute-by-minute basis. (This is a rough-and-ready comparison because the scales and the standard deviation of the two graphs really need to be matched to get a proper overlay).

Peter



To: Biomaven who wrote (4042)5/13/2002 11:37:29 AM
From: tuck  Read Replies (1) | Respond to of 52153
 
Peter,

As Niaspan/Advicor presents some safety issues (with both parts of the combo), I wondered if you were following competing programs, such as Esperion's APO A-1 Milano and Pfizer's CETP, and had any thoughts about them. I've been doing some digging and posted a few abstracts on the ESPR thread.

Cheers, Tuck